Early access
Sign in
Not yet taking people in ItalyPhase 2

Long-term safety of oral KT-621 in people with eosinophilic asthma

Checks long-term safety of KT-621 in adults who took part in an earlier asthma study.

Key facts

Who runs it
Kymera Therapeutics Inc.
Where
Bari, Genoa, Milan, Naples, and Rome, ItalySee the 6 sitesAlso in 7 other countries, 35 sites
Registry title
A Long-term Study of KT-621 Administered Orally to Participants with Asthma Previously Enrolled in a KT-621 Asthma Study
Status
Not yet recruiting
Phase
Phase 2
People taking part
77 people, planned
Started
1 Sept 2026
Expected to end
31 Dec 2028
Type of study
Interventional
Record updated
23 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with asthma who finished an earlier KT-621 asthma study. It checks the long-term safety of the pill KT-621.

Age
18 years and older
Sex
All sexes can join.
Disease stage
Uncontrolled moderate to severe eosinophilic asthma.
Earlier treatment
Must have completed all visits of the earlier KT-621 asthma study, up to the end of treatment visit. Must not have stopped study treatment for good in that study.

Main reasons for not taking part

  • Clinically significant change in health during the earlier study that could affect safety or study visits
  • Side effect in the earlier study that could make continued treatment an unreasonable risk
  • Study treatment permanently stopped in the earlier study
  • Member of the sponsor's or site's study team, or their immediate family
  • Any other reason the investigator judges unsuitable, including likely not following study procedures

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Must have completed all visits of the parent study, per its protocol, up to the end of treatment (EoT) visit
  • Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol
  • Must agree to contraceptive requirements in compliance with the clinical study and local requirements

Who cannot take part

  • Must not have experienced any clinically significant change in health status during the parent study, which, in the opinion of the Investigator, would interfere with participant safety, study evaluations, or compliance with study procedures; or otherwise make the participant unsuitable for participation in this study
  • Must not have developed an AE during the parent study, that in the opinion of the Investigator or of the Sponsor's Medical Monitor, could indicate that continued treatment may present an unreasonable risk for the participant
  • Must not have met permanent discontinuation criteria and/or permanently discontinued study treatment for any reason during the parent study
  • Must not be a member of the Sponsor or site's investigational team or their immediate family
  • Must not be unsuitable to enter the study for any other reason, as judged by the Investigator, including potential risk of noncompliance to study procedures

Where in Italy

Also in 7 other countries, 35 sites

  • Azienda Universitaria Ospedaliera Consorziale Policlinico BariBari, ItalyNot yet recruiting
  • IRCCS Azienda Ospedaliera MetropolitanaGenoa, ItalyNot yet recruiting
  • Azienda Socio Sanitaria Territoriale Santi Paolo E CarloMilan, ItalyNot yet recruiting
  • Azienda Ospedaliera dei ColliNaples, ItalyNot yet recruiting
  • Azienda Ospedaliera Policlinico Universitario Tor VergataRome, ItalyNot yet recruiting
  • Azienda Ospedaliero-Universitaria Sant AndreRome, ItalyNot yet recruiting

About the trial

What the trial wants to find out

To evaluate the long-term safety and tolerability of KT-621 in participants with asthma

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
Plain-language title
Long-term safety of oral KT-621 in people with eosinophilic asthmaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
23 September 2026